In the featured article from the February 2017 issue of The Journal of Nuclear Medicine, researchers document the first-in-human application of a new imaging agent to help find prostate cancer in both early and advanced stages and plan treatment. The study indicates that the new agent—a PET radiotracer—is both safe and effective.
The new agent is a gallium-68 (Ga-68)-labeled peptide BBN-RGD agent that targets both gastrin-releasing peptide receptor (GRPR) and integrin ?v?3. Dual-receptor targeting provides advantages over single-receptor targeting by allowing tumor contrast when either or both receptor types are expressed, improving binding affinity and increasing the number of effective receptors.
Approximately one in seven men will be diagnosed with prostate cancer in his lifetime. In 2017, the American Cancer Society estimates that there will be more than 161,000 new prostate cancer cases in the United States and around 27,000 deaths from the disease. “Although treatable at the early stage, prostate cancer is prone to metastasis,” explain the team of authors, led by Xiaoyuan Chen, senior investigator, Laboratory of Molecular Imaging and Nanomedicine at the U.S. National Institute of Biomedical Imaging and Bioengineering. “An effective and specific imaging method of detecting both primary and metastatic lesions is thus of critical importance to manage patients with prostate cancer.”
This study included 13 patients with prostate cancer (four newly diagnosed and nine post-therapy) and five healthy volunteers. Ga-68-BBN-RGD PET/CT detected 20 bone lesions in seven patients either with primary prostate cancer or after radical prostatectomy. The patients with bone metastases did not necessarily have an elevated prostate specific antigen level. “This result is better than bone scanning with MDP,” Chen notes, referring to the most common radiotracer used today. “MDP bone scans are sensitive but lack specificity because localized skeletal accumulation of Tc-99m-MDP can also be observed in the case of trauma and infection.” No adverse side effects were found during the whole procedure and two-week follow-up, demonstrating the safety of Ga-68-BBN-RGD.
“Compounds capable of targeting more than one biomarker have the ability of binding to both early and metastatic stages of prostate cancer, creating the possibility for a more prompt and accurate diagnostic profile for both primary and the metastatic tumors,” explains Chen.
Looking ahead, Chen says, “Ga-68-BBN-RGD could play an additive role in staging and detecting prostate cancer and provide guidance for internal radiation therapy using the same peptide labeled with therapeutic radionuclides.” He points out that larger-scale clinical investigations are warranted.
Learn more: New Type of PET Imaging Identifies Primary and Metastatic Prostate Cancer
[osd_subscribe categories=’prostate-cancer’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “PROSTATE CANCER”‘]
Receive an email update when we add a new PROSTATE CANCER article.
The Latest on: Prostate cancer
[google_news title=”” keyword=”prostate cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Prostate cancer
- Cornwall man diagnosed with prostate cancer despite having no symptomson May 1, 2024 at 8:31 pm
A man from St Austell who was diagnosed with prostate cancer despite having no symptoms says he may not be alive if he hadn't got checked out. | ITV News ...
- Research improves early detection of prostate canceron May 1, 2024 at 5:40 pm
A process developed in Australia that accurately identifies prostate cancer in low-risk patients is being used in ...
- UCL to co-lead Prostate Cancer UK's new £42m screening trialon May 1, 2024 at 5:00 pm
UCL academics will co-lead Prostate Cancer UK's new £42m screening trial, which aims to find the best way to screen men for prostate cancer and double the number of lives saved. The TRANSFORM trial ...
- A new hope for men with metastatic prostate canceron May 1, 2024 at 3:07 pm
Explore a groundbreaking new therapy for metastatic prostate cancer. Learn about the promising results of the Actinium-225 clinical trial at McGill University Health Centre.
- ‘Game-Changing’ Prostate Cancer Screening Trial Could Cut Deaths by 40%on May 1, 2024 at 9:05 am
With no current screening programme in the UK, experts believe this £42m project is a ‘pivotal moment’ in the fight against prostate cancer ...
- Prostate cancer survivor sheds light on common stigmason May 1, 2024 at 6:01 am
“Because symptoms often don't appear before the cancer is at a more advanced stage, we need to be much louder about prostate cancer awareness and utilizing early detection as the first line of defense ...
- New Screening Protocol Detects Aggressive Prostate Canceron May 1, 2024 at 3:47 am
A new three-step prostate cancer screening method shows promise in detecting aggressive cancers while minimizing unnecessary diagnoses.
- Plant-based diet tied to improved sexual health, slower disease progression in men with prostate canceron May 1, 2024 at 2:13 am
Researchers say a plant-based diet can help ease the side effects for men being treated for prostate cancer, especially those involving sexual health. Another study also reveals that a plant-based ...
- The nine things every man should know about prostate canceron May 1, 2024 at 1:23 am
Opening up about their below-the-belt health is not a conversation every man wants to have with his doctor, let alone his nearest and dearest – but the fact remains that every 45 minutes one man dies ...
via Bing News